EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial

Abhishek A Solanki iD, William Adams iD, James A Proudfoot, Kristin Baldea, Güliz A Barkan, Alec M Block, Neil B Desai iD, Ahmer Farooq, Michael R Folkert iD, Aurelie Garant iD, Alex Gorbonos, Gopal Gupta iD und 13 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-02730 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Abhishek A Solanki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Salvage Therapy, Neoplasm Recurrence, Local. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification.

Methods

F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS).

Results

Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence.

Conclusion

DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapySalvage TherapyNeoplasm Recurrence, LocalHumansMaleAgedMiddle AgedRisk AssessmentAged, 80 and overRadiotherapy DosageGenomicsQuality of Life

Autor:innen und Institutionen

  • Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.
  • Loyola University Medical Center, Maywood, IL.
  • Department of Medicine, Loyola University Chicago, Maywood, IL.
  • Veracyte, Inc, San Diego, CA.
  • Department of Urology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.
  • Department of Pathology and Laboratory Medicine, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.

ORCID-Profile: Abhishek A Solanki, William Adams, Neil B Desai, Michael R Folkert, Aurelie Garant, Gopal Gupta, Hyejoo Kang, Steven Kregel, Stanley L Liauw, William Small, Matthew M Harkenrider

Zitieren

APA

Solanki, A. A., Adams, W., Proudfoot, J. A., Baldea, K., Barkan, G. A., Block, A. M., Desai, N. B., Farooq, A., Folkert, M. R., Garant, A., Gorbonos, A., Gupta, G., Kang, H., Kelly, E., Kregel, S., Liauw, S. L., Luminais, C. K., Mysz, M., Quek, M. L., …, & Harkenrider, M. M. (2026). Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02730

Vancouver

Solanki AA, Adams W, Proudfoot JA, Baldea K, Barkan GA, Block AM, et al. Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02730

BibTeX
@article{Solanki2026,
  author = {Solanki, Abhishek A and Adams, William and Proudfoot, James A and Baldea, Kristin and Barkan, Güliz A and Block, Alec M and Desai, Neil B and Farooq, Ahmer and Folkert, Michael R and Garant, Aurelie and Gorbonos, Alex and Gupta, Gopal and Kang, Hyejoo and Kelly, Eileen and Kregel, Steven and Liauw, Stanley L and Luminais, Christopher K and Mysz, Michael and Quek, Marcus L and Showalter, Timothy N and Welsh, James S and Woods, Michael and Davicioni, Elai and Small, William and Harkenrider, Matthew M},
  title = {Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-02730}
}
Kostenlos starten →